Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Peter Schmid

Has grant

Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine

Barts Cancer Institute

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom

Recent Grants

Grant: Open

DIAMOND - An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer

Open Date: 2025-03-01

Close Date: 2029-12-01

Grant: Open

Barts ECMC

Open Date: 2023-04-01

Close Date: 2028-03-01

Grant: Open

BARBICAN: A randomized, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

Open Date: 2018-07-01

Close Date: 2027-05-01

Grant: Close

ECLIPSE - A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer

Open Date: 2017-12-01

Close Date: 2024-12-01

Grant: Close

Comprehensive Analysis of Circulating Biomarkers in breast cancer patients

Open Date: 2015-01-01

Close Date: 2018-01-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Collaborators (14)

Ardeshir Hanifi

Dr. at KTH Royal Institute of Technology

KTH Royal Institute of Technology

SWEDEN

View details

Sheeba Irshad

King’s College London

UNITED KINGDOM

View details

Karen Pinilla Alba

Assistant Research Professor

University of Cambridge

UNITED KINGDOM

View details

Sherene Loi

University of Melbourne

AUSTRALIA

View details

Joohyuk Sohn

Yonsei University College of Medicine

SOUTH KOREA

View details

Lucia Del Mastro

dirigente medico

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro

ITALY

View details

Jean Abraham

Professor of Precision Breast Cancer Medicine

University of Cambridge

UNITED KINGDOM

View details

Seock-Ah Im

Professor

Seoul National University College of Medicine

SOUTH KOREA

View details

Stuart McIntosh

Professor of Surgical Oncology

The Queen's University Belfast

UNITED KINGDOM

View details

Kyung Hae Jung

University of Ulsan College of Medicine

SOUTH KOREA

View details

Giampaolo Bianchini

Head Breast Cancer Group

IRCCS Ospedale San Raffaele

ITALY

View details

Ricardo Fernandes

Western University

CANADA

View details

Jacek Jassem

professor

Medical University of Gdansk

POLAND

View details

Rebecca Burrell

NIHR Academic Clinical Lecturer

University of Cambridge

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Schmid

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro in participants (pts) with previously untreated PD-L1+metastatic triple-negative breast cancer (mTNBC)

ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

ELEGANT: Elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study

Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2-eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

Impact of an online educational activity on oncologists' knowledge and confidence regrading novel antibody-drug conjugate strategies for breast cancer management

Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab plus Trastuzumab plus Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.

OPERA-01: a phase III study of palazestrant for ER+, HER2-advanced breast cancer after CDK4/6 inhibitor therapy

OPERA-02: A phase 3 study of palazestrant plus ribociclib as first-line treatment of ER+, HER2-advanced breast cancer.

Optimal three-dimensional perturbations in fluttering and non-fluttering bioprosthetic aortic valves

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer ( vol 22, pg 2469, 2018)

Collaborators (14)

Ardeshir Hanifi

Sheeba Irshad

Karen Pinilla Alba

Sherene Loi

Joohyuk Sohn

Lucia Del Mastro

Jean Abraham

Seock-Ah Im

Stuart McIntosh

Kyung Hae Jung

Giampaolo Bianchini

Ricardo Fernandes

Jacek Jassem

Rebecca Burrell

Make your next move.